Merrimack Strengthens SHERLOC Study of MM-121 in Non-small Cell Lung Cancer

March 12, 2018

Responsive image

CAMBRIDGE, Mass., March 12, 2018 /PRNewswire/ — Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK), a clinical-stage oncology company focused on biomarker-defined cancers, today announced that it is expanding enrollment in the ongoing randomized Phase 2 SHERLOC study of its investigational dr…

Category: Precious Metals